The Behavioral Assessment and Medical (BAM) Core is a new component of the competing TMARC renewal, that merges the Clinical Assessment and Laboratory (CAL) and Neuropsychiatric (NP) Cores from the prior funding period to improve resource efficiency. Now comprised of the Neuromedical and Laboratory Unit (NLU) and the Neuropsychiatric Unit (NPU), the BAM Core will extensively contribute to Center objectives by providing to TMARC Projects and Scientific Cores: 1) comprehensive neuromedical and neurobehavioral characterization of human participants, 2) specimen collection/management, and 3) collaboration and training regarding the analyses/interpretation of neuromedical, laboratory, and neurobehavioral data. Standardized neuromedical assessments will focus on aspects of health affected by HIV, METH and aging, including participants'medical and treatment history, neurological functioning, HIV disease staging, and medical comorbidity status (e.g., VACS Index, frailty). Laboratory assessments will include tests for co-infections, clinical lab assays (e.g., hepatic transaminases, hemoglobin), and soluble and cellular biomarkers in cerebrospinal fluid and blood that reflect HIV replication, immune functioning, and oxidative stress. New measures of biologic aging - cell senescence (telomere shortening) and mitochondrial aging (mtDNA injury) are added in support of TMARC's aging theme. The NLU also will provide assays for TMARC's animal projects and support for TMARC's pilot project on cell senescence. The NPU will provide comprehensive neurobehavioral assessments, including neurocognitive abilities, complex frontal systems behaviors (impulsivity/disinhibition, sensation-seeking, and apathy), comorbid psychiatric conditions (mood, ADHD, ASPD, and substance-related), plus key outcomes such as ART adherence, risky behaviors (unsafe sex, drug use, driving), performance-based lADL assessments, independence in real world functioning (e.g., lADLs, employment, health role functioning), psychosocial functioning (social and emotional functioning, quality of life) and support for TMARC's pilot project examining the utility of novel, virtual reality tasks to assess the everyday impact of neurobehavioral impairments due to METH, HIV and aging.
The BAM Core is central to TMARC's major scientific aim of understanding the CNS consequences of METH and HIV within the context of aging. BAM Core data will enable studies investigating the pathogenesis and functional consequences of HIV and METH that may lead to more targeted interventions for reducing the public health impact of these increasingly prevalent conditions across the lifespan.
|Morgan, Erin E; Iudicello, Jennifer E; Cattie, Jordan E et al. (2015) Neurocognitive impairment is associated with lower health literacy among persons living with HIV infection. AIDS Behav 19:166-77|
|Casaletto, K B; Obermeit, L; Morgan, E E et al. (2015) Depression and executive dysfunction contribute to a metamemory deficit among individuals with methamphetamine use disorders. Addict Behav 40:45-50|
|Maung, Ricky; Hoefer, Melanie M; Sanchez, Ana B et al. (2014) CCR5 knockout prevents neuronal injury and behavioral impairment induced in a transgenic mouse model by a CXCR4-using HIV-1 glycoprotein 120. J Immunol 193:1895-910|
|Morgan, Erin E; Doyle, Katie L; Minassian, Arpi et al. (2014) Elevated intraindividual variability in methamphetamine dependence is associated with poorer everyday functioning. Psychiatry Res 220:527-34|
|Kamat, Rujvi; Brown, Gregory G; Bolden, Khalima et al. (2014) Apathy is associated with white matter abnormalities in anterior, medial brain regions in persons with HIV infection. J Clin Exp Neuropsychol 36:854-66|
|Montoya, Jessica L; Georges, Shereen; Poquette, Amelia et al. (2014) Refining a personalized mHealth intervention to promote medication adherence among HIV+ methamphetamine users. AIDS Care 26:1477-81|
|Desplats, Paula; Dumaop, Wilmar; Cronin, Peter et al. (2014) Epigenetic alterations in the brain associated with HIV-1 infection and methamphetamine dependence. PLoS One 9:e102555|
|Henry, Brook L; Geyer, Mark A; Buell, Mahalah R et al. (2014) Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine. Behav Pharmacol 25:12-22|
|Tatro, Erick T; Purnajo, Intan; Richman, Douglas D et al. (2014) Antibody response to Achromobacter xylosoxidans during HIV infection is associated with lower CD4 levels and increased lymphocyte activation. Clin Vaccine Immunol 21:46-50|
|Iudicello, Jennifer E; Morgan, Erin E; Gongvatana, Assawin et al. (2014) Detrimental impact of remote methamphetamine dependence on neurocognitive and everyday functioning in older but not younger HIV+ adults: evidence for a legacy effect? J Neurovirol 20:85-98|
Showing the most recent 10 out of 44 publications